Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -84.57% | -16.53% | -21.35% | 13.77% | 147.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -84.57% | -16.53% | -21.35% | 13.77% | 147.98% |
| Cost of Revenue | -17.30% | -29.16% | -48.42% | -35.83% | -38.21% |
| Gross Profit | -185.98% | 35.58% | 55.55% | 43.72% | 170.00% |
| SG&A Expenses | -24.29% | -42.86% | -4.08% | -39.01% | -16.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.78% | -31.96% | -43.42% | -36.43% | -34.58% |
| Operating Income | -296.90% | 37.62% | 48.42% | 42.72% | 130.97% |
| Income Before Tax | -234.57% | 49.32% | 33.16% | -16.54% | 76.01% |
| Income Tax Expenses | 105.56% | -314.29% | -103.48% | -- | -325.00% |
| Earnings from Continuing Operations | -235.10% | 49.34% | 35.45% | -16.54% | 76.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -235.10% | 49.34% | 35.45% | -16.54% | 76.05% |
| EBIT | -296.90% | 37.62% | 48.42% | 42.72% | 130.97% |
| EBITDA | -267.43% | 37.82% | 49.47% | 44.04% | 136.20% |
| EPS Basic | -72.12% | 67.61% | 37.42% | -12.66% | 77.15% |
| Normalized Basic EPS | -385.15% | 55.23% | 41.25% | 36.92% | 112.47% |
| EPS Diluted | -72.12% | 67.61% | 37.42% | -12.66% | 77.15% |
| Normalized Diluted EPS | -385.15% | 55.23% | 41.25% | 36.92% | 112.47% |
| Average Basic Shares Outstanding | 94.69% | 56.41% | 3.16% | 3.44% | 4.80% |
| Average Diluted Shares Outstanding | 94.69% | 56.41% | 3.16% | 3.44% | 4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |